The roots of UTC Therapeutics begin back at the University of Pennsylvania (UPENN), where our founder Dr. Yangbing Zhao was an associate professor and the Director of the T Cell Engineering Lab, and co-founder Dr. Xiaojun Liu was the Deputy Director. As a renowned pioneer in adoptive T cell therapy, Dr. Zhao's past research contributed greatly to the field of cancer immunotherapies, including first two approved CAR-T therapies: Kymeriah and Yescarta.

Apart from being highly involved in the collaboration with Novartis on the research and development on CAR-T pipelines, Dr. Zhao also co-founded Tmunity Therapeutics with his colleagues at UPENN in 2015. Tmunity was a biotech company providing next-generation T-cell therapy to overcome TME challenges and raised over $200 millions.

Founded in 2019 by Dr. Zhao, Dr. Liu and Dr. Daniel Song, who was previously a Director at Johnson & Johnson, UTC Therapeutics is a clinical stage biotech company focusing on cancer immunotherapies.

Currently, UTC Therapeutics has more than 10 pipelines targeting hematological and solid cancers. We aspire to bring hope to cancer patients with our own multiple proprietary modalities, such as the LACO-Stim, a T-cell enhancing platform, mRNA, and an antibody-affinity optimization platform.